Down-regulation of miR-214 reverses erlotinib resistance in non-small-cell lung cancer through up-regulating LHX6 expression. [electronic resource]
Producer: 20180905Description: 781 p. digitalISSN:- 2045-2322
- 3' Untranslated Regions
- Antineoplastic Agents -- pharmacology
- Carcinoma, Non-Small-Cell Lung -- genetics
- Cell Line, Tumor
- Drug Resistance, Neoplasm -- genetics
- ErbB Receptors -- genetics
- Erlotinib Hydrochloride -- pharmacology
- Gene Expression Regulation, Neoplastic -- drug effects
- Humans
- LIM-Homeodomain Proteins -- genetics
- Lung Neoplasms -- genetics
- MicroRNAs -- genetics
- Nerve Tissue Proteins -- genetics
- Protein Kinase Inhibitors -- pharmacology
- RNA Interference
- Transcription Factors -- genetics
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.